| scholarly article | Q13442814 |
| P356 | DOI | 10.1093/CID/CIS474 |
| P698 | PubMed publication ID | 22573856 |
| P50 | author | Marleen Boelaert | Q28817180 |
| Vijay K Prajapati | Q63420767 | ||
| P2093 | author name string | Bart Ostyn | |
| Jean-Claude Dujardin | |||
| Shyam Sundar | |||
| Anup Singh | |||
| Jaya Chakravarty | |||
| Madhukar Rai | |||
| Avinash K Singh | |||
| P433 | issue | 4 | |
| P921 | main subject | India | Q668 |
| miltefosine | Q411787 | ||
| visceral leishmaniasis | Q2046113 | ||
| P304 | page(s) | 543-550 | |
| P577 | publication date | 2012-05-09 | |
| P1433 | published in | Clinical Infectious Diseases | Q5133764 |
| P1476 | title | Efficacy of miltefosine in the treatment of visceral leishmaniasis in India after a decade of use | |
| P478 | volume | 55 |
| Q38088424 | (Post-) Genomic approaches to tackle drug resistance in Leishmania. |
| Q58842850 | A Leishmania infantum genetic marker associated with miltefosine treatment failure for visceral leishmaniasis |
| Q64230550 | A chronic bioluminescent model of experimental visceral leishmaniasis for accelerating drug discovery |
| Q37465295 | A mitochondrial HSP70 (HSPA9B) is linked to miltefosine resistance and stress response in Leishmania donovani |
| Q37124150 | Amphiphilic Antimony(V) Complexes for Oral Treatment of Visceral Leishmaniasis |
| Q43177224 | Amphotericin B formulations and other drugs for visceral leishmaniasis |
| Q34945204 | An update on pharmacotherapy for leishmaniasis |
| Q34435696 | Antileishmanial activity of a series of N²,N⁴-disubstituted quinazoline-2,4-diamines |
| Q33659312 | Antimony transport mechanisms in resistant leishmania parasites. |
| Q36616938 | Antimony-resistant but not antimony-sensitive Leishmania donovani up-regulates host IL-10 to overexpress multidrug-resistant protein 1. |
| Q38777214 | Antitrypanosomal activity of 5-nitro-2-aminothiazole-based compounds |
| Q91817490 | Applications of Nanomaterials in Leishmaniasis: A Focus on Recent Advances and Challenges |
| Q49230063 | Arginine and Polyamines Fate in Leishmania Infection. |
| Q64107233 | Assessment of quality of life using WHOQOL-BREF in patients with visceral leishmaniasis |
| Q61442932 | Cell death pathways in pathogenic trypanosomatids: lessons of (over)kill |
| Q28553952 | Characterization of a Novel Endoplasmic Reticulum Protein Involved in Tubercidin Resistance in Leishmania major |
| Q46713325 | Chemotherapeutics of visceral leishmaniasis: present and future developments |
| Q39011875 | Chemotherapy of leishmaniasis: present challenges |
| Q37377400 | Chronic arsenic exposure and microbial drug resistance |
| Q35822187 | Clinico-epidemiological analysis of Post kala-azar dermal leishmaniasis (PKDL) cases in India over last two decades: a hospital based retrospective study. |
| Q38514270 | Co-infection of visceral leishmaniasis and HIV-1: a surviving case in China and review of treatment strategies |
| Q28073426 | Current challenges in treatment options for visceral leishmaniasis in India: a public health perspective |
| Q56565594 | Cyclin-dependent kinase 12 is a drug target for visceral leishmaniasis |
| Q28550454 | Decline in Clinical Efficacy of Oral Miltefosine in Treatment of Post Kala-azar Dermal Leishmaniasis (PKDL) in India |
| Q46380663 | Drug resistance and treatment failure in leishmaniasis: A 21st century challenge. |
| Q30248243 | Drug resistance in eukaryotic microorganisms |
| Q35249954 | Effectiveness and safety of short course liposomal amphotericin B (AmBisome) as first line treatment for visceral leishmaniasis in Bangladesh |
| Q50088426 | Efficacy and Safety of Liposomal Amphotericin B for Visceral Leishmaniasis in Children and Adolescents at a Tertiary Care Center in Bihar, India |
| Q28543060 | Efficacy and safety of amphotericin B emulsion versus liposomal formulation in Indian patients with visceral leishmaniasis: a randomized, open-label study |
| Q55464876 | Efficacy and safety of miltefosine in treatment of post-kala-azar dermal leishmaniasis. |
| Q30244956 | Elimination of visceral leishmaniasis on the Indian subcontinent |
| Q37712969 | Elucidation of cellular mechanisms involved in experimental paromomycin resistance in Leishmania donovani |
| Q36641747 | Evaluation of rK-39 strip test using urine for diagnosis of visceral leishmaniasis in an endemic region of India |
| Q28551055 | Evolutionary genomics of epidemic visceral leishmaniasis in the Indian subcontinent |
| Q46921246 | Experimental selection of paromomycin and miltefosine resistance in intracellular amastigotes of Leishmania donovani and L. infantum |
| Q21132005 | Failure of miltefosine treatment for visceral leishmaniasis in children and men in South-East Asia |
| Q90305680 | Field effectiveness of new visceral leishmaniasis regimens after 1 year following treatment within public health facilities in Bihar, India |
| Q57805342 | Field safety and effectiveness of new visceral leishmaniasis treatment regimens within public health facilities in Bihar, India |
| Q51783447 | First report of Leishmania infantum infection in the endangered orangutan (Pongo pygmaeus pygmaeus) in Madrid, Spain. |
| Q28538265 | Five-year field results and long-term effectiveness of 20 mg/kg liposomal amphotericin B (Ambisome) for visceral leishmaniasis in Bihar, India |
| Q27304615 | Generation of luciferase-expressing Leishmania infantum chagasi and assessment of miltefosine efficacy in infected hamsters through bioimaging |
| Q37023262 | Genomic Appraisal of the Multifactorial Basis for In Vitro Acquisition of Miltefosine Resistance in Leishmania donovani |
| Q36001763 | Genomic and Molecular Characterization of Miltefosine Resistance in Leishmania infantum Strains with Either Natural or Acquired Resistance through Experimental Selection of Intracellular Amastigotes |
| Q47252456 | Identification and Functional Validation of a Biomarker for the Diagnosis of Miltefosine Relapse during Visceral Leishmaniasis |
| Q90661828 | Identification of GSK3186899/DDD853651 as a Preclinical Development Candidate for the Treatment of Visceral Leishmaniasis |
| Q34054948 | Immunotherapy and targeted therapies in treatment of visceral leishmaniasis: current status and future prospects |
| Q90557307 | Impact of sequelae of visceral leishmaniasis and their contribution to ongoing transmission of Leishmania donovani |
| Q90125299 | Impaired development of a miltefosine-resistant Leishmania infantum strain in the sand fly vectors Phlebotomus perniciosus and Lutzomyia longipalpis |
| Q30380900 | In vitro selection of miltefosine resistance in promastigotes of Leishmania donovani from Nepal: genomic and metabolomic characterization. |
| Q37225817 | In vitro susceptibility of Leishmania donovani to miltefosine in Indian visceral leishmaniasis |
| Q33797614 | Increased miltefosine tolerance in clinical isolates of Leishmania donovani is associated with reduced drug accumulation, increased infectivity and resistance to oxidative stress |
| Q38269581 | Investigational drugs for visceral leishmaniasis |
| Q37615730 | Laboratory confirmed miltefosine resistant cases of visceral leishmaniasis from India |
| Q41990715 | Leishmania and other intracellular pathogens: selectivity, drug distribution and PK-PD. |
| Q28082283 | Leishmaniasis revisited: Current aspects on epidemiology, diagnosis and treatment |
| Q57293286 | Lipase precursor like protein promotes miltefosine tolerance in by enhancing parasite infectivity and eliciting anti-inflammatory responses in host macrophages |
| Q36456032 | Liposomal amphotericin B as a treatment for human leishmaniasis |
| Q35690135 | Long-term follow-up of dogs with leishmaniosis treated with meglumine antimoniate plus allopurinol versus miltefosine plus allopurinol |
| Q92141834 | Lupeol induces immunity and protective efficacy in a murine model against visceral leishmaniasis |
| Q55106221 | Macrophage Activation Marker Neopterin: A Candidate Biomarker for Treatment Response and Relapse in Visceral Leishmaniasis. |
| Q40067217 | Miltefosine Resistant Field Isolate From Indian Kala-Azar Patient Shows Similar Phenotype in Experimental Infection |
| Q40084369 | Mitochondria and lipid raft-located FOF1-ATP synthase as major therapeutic targets in the antileishmanial and anticancer activities of ether lipid edelfosine. |
| Q87791722 | Mixed antimony(V) complexes with different sugars to modulate the oral bioavailability of pentavalent antimonial drugs |
| Q92765735 | Natural Resistance of Leishmania infantum to Miltefosine Contributes to the Low Efficacy in the Treatment of Visceral Leishmaniasis in Brazil |
| Q37308658 | Nitrotriazole-based acetamides and propanamides with broad spectrum antitrypanosomal activity. |
| Q39373535 | Pharmacovigilance of Miltefosine in Treatment of Visceral Leishmaniasis in Endemic Areas of Bihar, India |
| Q28074697 | Plasticity of the Leishmania genome leading to gene copy number variations and drug resistance |
| Q47106631 | Post-kala-azar dermal leishmaniasis in the Indian subcontinent: A threat to the South-East Asia Region Kala-azar Elimination Programme |
| Q57166879 | Recent Development of Visceral Leishmaniasis Treatments: Successes, Pitfalls, and Perspectives |
| Q26740563 | Recent developments and future prospects in the treatment of visceral leishmaniasis |
| Q27011766 | Recent developments in drug discovery for leishmaniasis and human African trypanosomiasis |
| Q24611966 | Relapse after treatment with miltefosine for visceral leishmaniasis is associated with increased infectivity of the infecting Leishmania donovani strain |
| Q35083515 | Risk factors for visceral leishmaniasis relapse in immunocompetent patients following treatment with 20 mg/kg liposomal amphotericin B (Ambisome) in Bihar, India |
| Q35952211 | SAR refinement of antileishmanial N(2),N(4)-disubstituted quinazoline-2,4-diamines |
| Q33783806 | Safety and efficacy of short course combination regimens with AmBisome, miltefosine and paromomycin for the treatment of visceral leishmaniasis (VL) in Bangladesh |
| Q35150268 | Single-dose indigenous liposomal amphotericin B in the treatment of Indian visceral leishmaniasis: a phase 2 study |
| Q26849297 | Strategies to overcome antileishmanial drugs unresponsiveness |
| Q50042596 | Synthesis and Evaluation of Methyl 4-(7-Hydroxy-4,4,8-Trimethyl-3-Oxabicyclo[3.3.1]Nonan-2-yl)Benzoate as an Antileishmanial Agent and Its Synergistic Effect with Miltefosine |
| Q37712177 | The lost hope of elimination of Kala-azar (visceral leishmaniasis) by 2010 and cyclic occurrence of its outbreak in India, blame falls on vector control practices or co-infection with human immunodeficiency virus or therapeutic modalities? |
| Q37333942 | Therapeutic options for visceral leishmaniasis |
| Q36326798 | To evaluate efficacy and safety of amphotericin B in two different doses in the treatment of post kala-azar dermal leishmaniasis (PKDL). |
| Q42379574 | Transcriptome profiling identifies genes/pathways associated with experimental resistance to paromomycin in Leishmania donovani |
| Q36094815 | Transmission Dynamics of Visceral Leishmaniasis in the Indian Subcontinent - A Systematic Literature Review |
| Q37544280 | Treatment failure and miltefosine susceptibility in dermal leishmaniasis caused by Leishmania subgenus Viannia species. |
| Q87271924 | Treatment of visceral leishmaniasis: options and choice |
| Q57944427 | Visceral leishmaniasis |
| Q54961274 | Why miltefosine-a life-saving drug for leishmaniasis-is unavailable to people who need it the most. |
Search more.